Objective: Infection with Epstein-Barr virus (EBV) has been associated with clinical activity and risk of developing MS. The purpose of this study is to investigate the impact of glatiramer acetate (GA) therapy on EBV-specific immune responses and disease course.
Methods: We characterized EBV-specific CD8 T lymphocytes and B cells during disease-modifying treatments in 2 groups of patients with MS. We designed a 2-pronged approach consisting of a cross-sectional study (39 untreated patients, 38 patients who had undergone 12 months of GA treatment, and 48 healthy donors compatible for age and sex with the patients with MS) and a 12-month longitudinal study (35 patients treated with GA). CD8 EBV-specific T cells and B lymphocytes were studied using pentamers and multiparametric flow cytometry.
Results: We find that treatment with GA enhances viral recognition by inducing an increased number of circulating virus-specific CD8 T cells ( = 0.0043) and by relieving their features of exhaustion ( = 0.0053) and senescence ( < 0.0001, = 0.0001). B cells, phenotypically and numerically tracked along the 1-year follow-up study, show a steady decrease in memory B-cell frequencies ( = 0.025), paralleled by an increase of the naive B subset.
Conclusion: GA therapy acts as a disease-modifying therapy restoring homeostasis in the immune system, including anti-EBV responses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455312 | PMC |
| http://dx.doi.org/10.1212/NXI.0000000000000876 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objectives: Dysregulation of Epstein-Barr virus (EBV)-specific cellular immunity has been hypothesised as one of the contributing factors in the pathogenesis of systemic lupus erythematosus (SLE). Lupus nephritis is a major risk factor for overall morbidity in SLE. Immune-based strategies directed to EBV have been proposed as potential therapeutic strategy for SLE and lupus nephritis.
View Article and Find Full Text PDFEpstein-Barr virus-specific T-cell response in pediatric liver transplant recipients: a cross-sectional study by multiparametric flow cytometry.
Front Immunol
November 2024
Clinical Immunology Department, University Hospital La Paz, Madrid, Spain.
Background: Epstein-Barr virus (EBV) specific T-cell response measurement can help adjust immunosuppression in transplant patients with persistent infections. We aim to define T-cell responses against EBV in a cohort of pediatric liver-transplant patients.
Methods: Thirty-eight immunosuppressed pediatric liver-transplant patients (IP) and 25 EBV-seropositive healthy-adult controls (HC) were included in our cross-sectional study.
Article Synopsis
- α/β T cells are essential for adaptive immunity, with their specificity determined by the unique sequences of their T cell receptor (TCR) chains.
- Traditional bulk TCR sequencing is cost-effective but lacks paired chain data, while single-cell methods provide this data but are expensive and low-throughput.
- The new method, TIRTL-seq, efficiently generates paired TCR libraries from live cells in under 7 hours, enabling extensive profiling of T cell responses with high scalability and reduced costs.
Article Synopsis
- Memory T cells are diverse and change over time, influenced by factors such as cytokines and antigen exposure, complicating the study of aging's effects on them.
- A study on Epstein-Barr virus (EBV) showed that memory CD8 T cells from young adults (<40 years) exhibit specific differentiation patterns, whereas older adults (>65 years) show distinct aging paths with diminished adaptive features but increased innate characteristics.
- Surprisingly, despite losing naïve/stem-like EBV-specific T cells with age, the overall diversity of EBV-specific memory T cells either remained stable or improved, providing insights for better vaccination and T cell therapy strategies.
Mechanistic Understanding of EBV+Lymphoproliferative Disease Development After Transplantation.
Transplantation
September 2024
Center for Virology, Medical University of Vienna, Vienna, Austria.
Posttransplant lymphoproliferative disorders (PTLDs) are among the most common malignant complications after transplantation, leading to a drastic reduction in patient survival rates. The majority of PTLDs are tightly linked to Epstein-Barr virus (EBV+PTLDs) and are the result of an uncontrolled proliferation of EBV-infected cells. However, although EBV infections are a common finding in transplant recipients, most patients with high EBV loads will never develop EBV+PTLD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!